Who are Replimune Group, Inc.'s main suppliers?

Replimune Group, Inc. (REPL) key suppliers include: Hercules Capital, Inc., Hercules Capital, Inc., ROCHE, Genelux Corporation. View the full supplier network at chainsifter.com/chain/REPL.

Who are Replimune Group, Inc.'s major customers?

Replimune Group, Inc. (REPL) key customers include: Bristol-Myers Squibb Company, Bristol-Myers Squibb Company, Bristol-Myers Squibb Co, Bristol-Myers Squibb Co, Genelux Corporation and 5 more. View the full customer network at chainsifter.com/chain/REPL.

What sector is Replimune Group, Inc. in?

Replimune Group, Inc. (REPL) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Replimune Group, Inc. Suppliers, Customers & Supply Chain (REPL)

4Suppliers

10Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Replimune Group, Inc. (REPL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

18Total relationships

4Distinct source URLs

7High confidence

0.790Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Replimune Group, Inc. Suppliers

Ticker	Name	Confidence	Evidence
HTGC	Hercules Capital, Inc.	90%	in significant future amortization expense or intangible asset impairment charges. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our abilit…
HTGC	Hercules Capital, Inc.	90%	Reciprocal relationship from HTGC graph: Reciprocal relationship from REPL graph: in significant future amortization expense or intangible asset impairment charges. Moreover, we may not be able to lo…
ROCHE	ROCHE	90%	The ongoing study in HCC is being developed in combination with atezolizumab and bevacizumab under a supply and clinical collaboration agreement with Roche.
GNLX	Genelux Corporation	72%	Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, producti…

Replimune Group, Inc. Customers

Ticker	Name	Confidence	Evidence
BMY	Bristol-Myers Squibb Company	72%	the Company's common stock, and 333,130 and 148,190 restricted stock units under employment inducement grants. Stock option valuation The fair value of stock option grants is estimated using the Blac…
BMY	Bristol-Myers Squibb Company	72%	Reciprocal relationship from BMY graph: Reciprocal relationship from REPL graph: Reciprocal relationship from BMY graph: Reciprocal relationship from REPL graph: Reciprocal relationship from BMY grap…
BMYMP	Bristol-Myers Squibb Co	72%	the Company's common stock, and 333,130 and 148,190 restricted stock units under employment inducement grants. Stock option valuation The fair value of stock option grants is estimated using the Blac…
BMYMP	Bristol-Myers Squibb Co	72%	Reciprocal relationship from BMYMP graph: Reciprocal relationship from REPL graph: the Company's common stock, and 333,130 and 148,190 restricted stock units under employment inducement grants. Stock…
GNLX	Genelux Corporation	72%	Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, producti…
HTGC	Hercules Capital, Inc.	72%	rkets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. A weak or declining economy or political disruptio…
HTGC	Hercules Capital, Inc.	72%	Reciprocal relationship from HTGC graph: Reciprocal relationship from REPL graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from REPL graph: Reciprocal relationship from HTGC g…
INTS	Intensity Therapeutics, Inc.	72%	Reciprocal relationship from INTS graph: Reciprocal relationship from REPL graph: Reciprocal relationship from INTS graph: Reciprocal relationship from REPL graph: Reciprocal relationship from INTS g…
REGN	Regeneron Pharmaceuticals, Inc.	72%	rchase shares of the Company's common stock, and and restricted stock units under employment inducement grants. Stock option valuation The fair value of stock option grants is estimated using the Bla…
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from REPL graph: rchase shares of the Company's common stock, and and restricted stock units under employment inducement grants. Stock…

Replimune Group, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
REPL-DEBT	Debt stack $84.1M	90%	Market cache reports total debt of $84.1M.
REPL-DEBT-12133	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2019-03-31.
REPL-DEBT-12132	Warrants outstanding: 5284238	90%	xbrl warrant detail from xbrl 2022-03-31.

Replimune Group, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Replimune Group, Inc..

Replimune Group, Inc. Ownership

Holder	Name	Confidence	Evidence
REPL-OWNER-BAKER-BROS-ADVISORS-LP	BAKER BROS. ADVISORS LP	90%	13F overlay lists BAKER BROS. ADVISORS LP as top holder; 187 tracked holders.

Replimune Group, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ATON	AlphaTON Capital Corp	100.00	2
BMYMP	Bristol-Myers Squibb Co	100.00	1	['customer']
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
ALEC	Alector, Inc.	100.00	2
CLLS	Cellectis S.A.	100.00	2
BMY	Bristol-Myers Squibb Company	100.00	1	['customer']
EMMA	Emmaus Life Sciences, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
CMPS	COMPASS Pathways plc	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
BEAM	Beam Therapeutics Inc.	100.00	2
HTGC	Hercules Capital, Inc.	100.00	1	['customer', 'supplier']
IRON	Disc Medicine, Inc.	100.00	2
ALT	Altimmune, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
BCYC	Bicycle Therapeutics plc	100.00	2
GNLX	Genelux Corporation	100.00	1	['customer', 'supplier']

Replimune Group, Inc. Supply Chain